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Apoptosis or programmed cell death selectively allows certain
cells to undergo cell death following many biological signals.
Apoptosis plays an important role in development and homeo-
stasis. In malignant cells, these physiological apoptotic pathways
are often disturbed, and as a result, they acquire uncontrolled
cellular survival and are often resistant to anti-tumour treatment
(Thompson et al, 1995).
The Fas (CD95/APO-1) and Fas ligand (FasL) pathway was
initially identified as a key system in the regulation of apoptosis
within the immune system (Nagata and Golstein, 1995). FasL with
its receptor, Fas, induces apoptosis in sensitized cells. This Fas-
mediated apoptosis is involved in thymocyte clonal deletion and
tolerance acquisition (Yonehara et al, 1994), T-cell activation-
induced cell death (Alderson et al, 1995), immune response termina-
tion (Daniel and Krammer, 1994) and T-cell-mediated cytotoxicity
(Ju et al, 1994). The Fas/FasL system has also been reported to have
roles in the maintenance of immune privilege in mouse testis
(Bellgrau et al, 1995) and in the anterior chamber of the eye (Griffith
et al, 1995). FasL expressed in these tissues induces apoptosis in
activated lymphocytes that infiltrate these sites.
In addition to being expressed in the immune system, Fas is
constitutively expressed by a broad panel of normal epithelial cells
(Leithauser et al, 1993). Although the roles of the Fas system in
non-lymphoid tissues are not thoroughly understood, a role in the
maintenance of physiological cell turnover has been suggested
(Keane et al, 1996; Suzuki et al, 1996). Fas expression and
response to it are variable in human lymphoid (Debatin and
Krammer, 1995; Shima et al, 1995) and non-lymphoid malignan-
cies (Owen-Schaub et al, 1994). Several studies have reported
decreased levels of Fas in cancer cells, and the resultant resistance
to Fas-mediated apoptosis may contribute to their escape from the
immune system (Leithauser et al, 1993; Moller et al, 1994; Keane
et al, 1996; Strand et al, 1996; Gratas et al, 1998). Furthermore,
recent studies have provided evidence that FasL expression is
found in various types of tumour cells. O’Connell et al (1996)
have proposed that FasL-expressing tumour cells counterattack
cytotoxic T-cells, which provides another mechanism by which
tumours can escape from the immune system.
Proliferation and regression of gynaecological tissues such as
ovary, cervix and endometrium is hormone-dependent, and Fas is
constitutively expressed in these tissues (Leithauser et al, 1993).
Thus, it would be interesting to know whether the expression of
Fas and/or FasL is also altered in these gynaecological cancers.
Although there have been reports concerning the expression of
these genes in gynaecological cancers, quantitative measurement
of the gene expression was not performed in those studies (Imai et
al, 1997; Takagi et al, 1998). Here, we investigated the relative
expression of Fas and FasL in human gynaecological carcinomas
of the ovary, cervix and endometrium using a recently developed,
highly sensitive quantitative real-time polymerase chain reaction
(PCR) system (Gibson et al, 1996).
MATERIALS AND METHODS
Tissue samples and cell lines
Expression of Fas and FasL genes was examined in 31 ovarian, 29
cervical and 25 endometrial carcinoma tissues, nine ovarian, six
cervical and eight endometrial normal tissues, and four ovarian
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specimens were obtained from the Hyogo Medical Center for
Adults adjoining to our Institute. The tumours were classified by
the Histo-Pathology Department of the Center according to the
WHO guidelines and staged according to the TNM classification
of malignant tumours defined by the International Union Against
Cancer. Normal tissue samples were collected from the site on the
body that was most distant from the tumours or from different
patients resected for a non-cancerous reason. All samples were
obtained with informed consent. Collected tissue samples were
snap-frozen in liquid nitrogen immediately after resection and
stored at –80°C unless used. Cervical carcinoma cell lines, HeLa
and CaSki, and T lymphoma cell line, Jurkat were obtained from
ATCC (Rockville, MD, USA). Another cervical carcinoma cell
line, DoT, was a gift of Dr R A Pattillo, Medical College of
Wisconsin, Wisconsin, USA. Ovarian carcinoma cell lines, RMG-
I, RMG-S, RTSG, RMUG-L, were gifts of Dr S Nozawa, Keio
University School of Medicine, Tokyo, Japan.
Standard RT-PCR for Fas and FasL mRNA
Total RNA was extracted from the frozen tissues and cultured cell
lines using TRIzol (Life Technologies, Inc., Gaithersburg, MD,
USA). One microgram of each total RNA was reverse transcribed
using a random hexamer and a SuperScript pre-amplification
system (Life Technologies). An aliquot of 1/20th of the resulting
cDNA was used for a PCR amplification. Fas primers were Fas I:
CAGAACTTGGAAGGCCTGCATC and Fas II: TCTGTTCT-
GCTGTGTCTTGGAC (O’Connell et al, 1996) which amplified a
fragment of 682 bp. Specific primers were FasL I: ACACCTATG-
GAATTGTCCTGC and FasL II: GACCAGAGAGAGCTCA-
GATACG, which amplified a fragment of 311 bp, and GAPDH I:
CATCACCATCTTCCAGGAGC and GAPDH II: GGATGAT-
GTTCTGGAGAGCC, which amplified a fragment of 404 bp.
These four primers were designed using the Gene Works software
program (IntelliGenetics, Inc., Mountain View, CA, USA). The
cDNA was amplified in 50 ml of PCR buffer containing dNTP,
magnesium chloride (MgCl2), using Ex-Taq DNA polymerase
(TaKaRa, Shuzo, Kyoto, Japan), and in a Peltier thermal cycler
(PTC-200; MJ Research, MA, USA). The annealing temperatures
for the specific primers, were 55°C for FasL and Fas, and 60°C 
for glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The
number of amplification cycles were 35 for FasL, 40 for Fas and
25 for GAPDH. The other conditions were the same, with initial
denaturation for 3 min at 94°C, cycle denaturation for 10 s at
92°C, annealing for 30 s and extension at 72°C for 60 s. A 10 ml
aliquot of amplified product was then analysed on a 2% Metaphor
agarose gel. Visualization and photography were performed with
the ImageMaster VDS (Pharmacia Biotech, Uppsala, Sweden), a
video documentation system for gel electrophoresis after ethidium
bromide staining.
Real-time quantitative PCR for Fas and FasL mRNA
To evaluate the expression of Fas and FasL, quantitative PCR was
performed using Sequence Detector (ABI PRISM 7700, P E
Applied Biosystems, Foster City, CA, USA). Selection of primers
and probes for Fas, FasL and GAPDH were performed by using
Primer Express software (P E Applied Biosystems). Selected
forward (F) and reverse (R) primers, and probes are as follows; Fas
F: 5¢ TGAAGGACATGGCTTAGAAGTG 3¢, Fas R: 5¢ GGT-
GCAAGGGTCACAGTGTT 3¢, Fas probe: 5¢-(FAM)- AAACTG-
CACCCGGACCCAGAATACC-(TAMRA)-3¢, FasL F: 5¢ GCAG-
CCCTTCAATTACCCAT 3¢, Fasl R: 5¢ CAGAGGTTGGACA-
GGGAAGAA 3¢, FasL probe: 5¢-(FAM)-TCCCCAGATCTAC-
TGGGTGGACAGC-(TAMRA)-3¢, GAPDH F: 5¢ GAAGGTGA-
AGGTCGGAGTC 3¢, GAPDH R: 5¢ GAAGATGGTGATGG-
GATTTC 3¢, GAPDH probe: 5¢-(FAM)-CAAGCTTCCCGT-
TCTCAGCC-(TAMRA)-3¢. These primer sets amplify 118 bp of
Fas, 101 bp of FasL, and 226 bp of GAPDH cDNA fragment
respectively. The TaqMan probes were used, which consisted of an
oligonucleotide with a 5¢ FAM (6-carboxy-fluorescein) reporter
dye and 3¢ quencher dye, TAMRA (6-carboxy-tetramethyl-
rhodamine). A portion (1/20) of each cDNA was used for quantita-
tive PCR in a 50 ml volume using Master Mix, which includes
PCR buffer, MgCl2, dATP, dCTP, dGTP, dUTP, AmpErase UNG
and AmpliTaq Gold DNA polymerase (P E Applied Biosystems).
Thermal cycling conditions were an initial 2 min at 50°C and 
10 min at 95°C, as recommended by the manufacturer. Cycle
conditions were 15 s at 95°C and 1 min at 60°C. For Fas and
GAPDH expression, 40 cycles of amplification were performed
and 50 cycles were performed for FasL expression.
Real-time quantitation was done based upon the TaqMan assay
using a fluorogenic oligonucleotide probe labelled with both a
fluorescent dye and a quencher dye according to manufacturer’s
instruction. In the intact TaqMan probe, the 5¢ fluorescent reporter
dye was quenched by the 3¢ quencher dye through a Foster-type
energy transfer. Fluorogenic DNA probes (TaqMan probes) were
hydrolysed during PCR upon hybridization to the template DNA
by Taq DNA polymerase, whose nuclease activity is dependent on
the 5¢ secondary structure. After hydrolysis, the release of the
reporter signal caused an increase in fluorescence intensity that
was proportional to the accumulation of the PCR product. The
fluorescence intensity of the reporter label was normalized using
the rhodamine derivative ROX as a passive reference label present
in the buffer solution. The system generates a real-time amplifica-
tion plot based upon the normalized fluorescence signal.
Subsequently the threshold cycle (CT), i.e. the fractional cycle
number at which the amount of amplified target reached a fixed
threshold was determined. The CT was then used for kinetic
analysis and was proportional to the initial number of target copies
in the sample. The starting quantity of a sample was calculated
after comparison of the CTs of a serial dilution of a positive
control. Figure 1 showed the amplification plots (left panel) and
the standard curves (right panel) of serially diluted positive
controls for Fas (1- to 128-fold), FasL (1- to 16 384-fold), and
GAPDH (1- to 64-fold) respectively. Jurkat was used as a positive
control for Fas expression, and DoT was used as a postive control
for FasL and GAPDH expression. Starting quantity of most diluted
positive control was defined as one.
Statistical analyses
Differences between expression levels of Fas or FasL among the
cancer patient group and the normal group of each type (ovarian,
cervical, endometrial) and also among the normal groups were
determined following the Mann–Whitney test using StatView soft-
ware (Abacus Concepts, Inc., Berkeley, CA, USA). The mean
values and standard deviations were presented in the respective
figure legends. Statistical significance was accepted when P < 0.05.
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Fas and FasL mRNA expression in ovarian cancer
tissues
We first analysed expression of Fas and FasL gene expression
along with GAPDH in ovarian cancer tissues by the standard RT-
PCR procedure (Figure 2). Many of the cancer tissues showed
decreased levels of Fas gene expression when the levels were
compared with those in normal ovarian tissues. The levels of FasL
gene expression varied among the samples. To obtain more accu-
rate data, we utilized the recently developed real-time quantitative
assay. Based on the standard curves which had the large dynamic
ranges for Fas (1–128), FasL (1–16 384), and GAPDH (1–64)
expression levels (Figure 1), Fas and FasL expression levels in the
samples were plotted after the levels were corrected with GAPDH
expression levels (Figure 3). In the primary ovarian cancer group
(n = 31), the levels of Fas expression were significantly decreased
(P < 0.001) compared with those in the normal group (n = 9). The
levels of FasL gene expression varied among the samples and
showed no significant difference when compared with those in
normal tissues. Decreased levels of Fas and FasL expression were
observed in the four ovarian carcinoma cell lines.
Fas and FasL mRNA expression in cervical cancer
tissues
A significant decrease in the levels of Fas gene expression were
also observed (P < 0.04) in the cervical carcinomas tissues (n = 29)
compared with those in the normal tissues (n = 6) (Figure 4).
Various levels of FasL gene expression were found in different
tissue samples. Two cancer tissues showed clearly increased levels
of FasL expression and some showed decreased levels. However,
no significant difference was found between the cancerous group
(P = 0.7593) and the respective normal group. Among the three
cervical carcinoma cell lines studied, only one (DoT) showed a
higher level of FasL, while the other two (HeLa and CaSki) did not
show any increase compared with the normal tissues.
Fas and FasL mRNA expression in endometrial cancer
tissues
Among 25 endometrial carcinoma samples evaluated with eight
normal tissues, levels of Fas gene expression were found to be
significantly decreased (P < 0.003) (Figure 5) as like as ovarian
and cervical samples. No significant difference (P = 0.2231) in the
levels of FasL gene expression was found between the cancerous
group and the normal group. Only one cancer tissue sample
showed a clearly increased level of FasL and some showed
decreased levels.
Comparison of Fas and FasL expression in normal
ovarian, cervical and endometrial tissues
Our results show that all the normal ovarian, cervical and endome-
trial tissues express certain levels of Fas and FasL (Figures 3–5).
The levels of Fas expression were not different among these
tissues while the levels of FasL expression in normal endometrial
tissues were about ninefold higher than those in the normal ovarian
tissues and about 12-fold higher than those in normal cervical
tissues.
DISCUSSION
RT-PCR assay is an excellent method to assess gene expression
due to its great sensitivity. Although PCR has provided a powerful
tool, it is imperative that it be used properly for quantitation. One
approach measures PCR product quantity in the log phase of the
reaction before the plateau (Kellogg et al, 1990). Another method,
quantitative competitive PCR, has been developed and is used
Fas and FasL in gynaecological cancers 1685
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Figure 2 Standard RT-PCR analysis of Fas and FasL expression in ovarian tumour (T) and normal (N). The corresponding expression of GAPDH is shown in
the lower panelwidely for PCR quantitation (Becker-Andre, 1991). Both methods,
however, are very time-consuming and cannot be used in a routine
setting. The final results sometimes vary, which make them hard to
assess and the use of the competitor DNA molecule in the compet-
itive PCR is a potential source of contamination. In contrast, DNA
amplification by the new method is detected in a closed tube, and
no post-PCR sample handling is necessary, thus minimizing cross-
sample contamination (Gibson et al, 1996). The instrument
provides real-time quantitative information and has a very large
dynamic range of starting target molecule determination (up to
five orders of magnitude). The same system has been used
successfully in the monitoring of leukaemia cells expressing
chimaeric genes (Mensink et al, 1998) and the measurement of
cytokine gene expression in lymphocytes (Rissoan et al, 1999).
With the advantage of real-time quantitative RT-PCR analysis in
this study, we demonstrated a statistically significant decrease in
the expression of Fas gene in the gynaecological carcinomas
compared with the respective normal tissues. Although Imai et al
(1997) have demonstrated frequent expression of Fas in endome-
trial and ovarian carcinomas, they did not show any quantitative
comparison with normal tissues. Our findings correlate with
earlier reports of decreased levels of Fas in primary breast carci-
nomas (Keane et al, 1996), oesophageal carcinomas (Gratas et al,
1998), hepatocellular carcinomas (Strand et al, 1996), colon carci-
nomas (Moller et al, 1994) and lung carcinomas (Leithauser et al,
1993). Thus, it appears that a loss or decrease in Fas gene expres-
sion may be one of the common changes that occur in a wide
variety of cancers. Recently, negative correlation of mutant Ras or
p53 expression with Fas gene expression has been reported in vitro
culture systems (Sheard et al, 1997; Fenton et al, 1998; Muller 
1686 H Das et al
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Figure 3 Real-time quantitative PCR analysis of Fas and FasL expression
in tumour (n) and normal (l) tissues, and cell lines (s) of ovarian 
origin. Statistical analyses of Fas; normal samples (n = 9) mean ± s.d.=
1053.7 ± 375.4, and tumour samples (n = 31) mean ± s.d.= 376.6 ± 385.4, 
P-values between tumour and normal is P < 0.001, and FasL; normal
samples mean ± s.d.= 15200.0 ± 13830.1, and tumour samples mean ± s.d.=
15046.4 ± 18257.7, P = 0.5490
Figure 5 Relative expression of Fas and FasL in tumour (n n) and normal
(l) tissues of endometrial origin corrected by GAPDH expression after real-
time quantitative PCR. Statistical analyses of Fas; normal samples (n = 8)
mean ± s.d.= 1495.8 ± 882.5, and tumour samples (n = 25) mean ± s.d.=
490.4 ± 518.8, P-values between tumour and normal is P < 0.003, and FasL;
normal samples mean ± s.d.= 134970.3 ± 155817.8, and tumour samples
mean ± s.d.= 143601.6 ± 366602.2, P = 0.2231
Figure 4 Relative expression of Fas and FasL in tumour (n) and normal
(l) tissues, and cell lines (s) of cervical origin corrected by GAPDH
expression after real-time quantitative PCR. Statistical analyses of Fas;
normal samples (n = 6) mean ± s.d.= 696.1 ± 228.4, and tumour samples 
(n = 29) mean ± s.d.= 432.9 ± 392.9, P-values between tumour and normal is
P < 0.04, and FasL; normal samples mean ± s.d.= 11371.3 ± 6788.6, and
tumour samples mean±s.d.= 19730.6 ± 31268.5, P = 0.7593et al, 1998). Further studies are required to answer the interesting
question of whether the decreased expression of the Fas gene
correlates with these major oncogenic processes in primary
cancers.
The resultant loss of Fas may make it easier for tumours to
survive and grow in spite of various anti-tumour mechanisms in
vivo (Zornig et al, 1995). The escape of Fas-negative tumours
from immune-attack by anti-tumour lymphocytes has been experi-
mentally demonstrated (Zornig et al, 1995). Tumour cells with
decreased levels of Fas may be resistant to cytotoxic drugs
(Micheau et al, 1997). Recently, it has been shown that apoptosis
induced by c-myc oncoprotein is dependent on Fas expression
(Hueber et al, 1997). Accordingly, the loss of Fas expression may
result in the resistance of c-myc-transformed tumour cells to
apoptosis and contribute to tumour growth.
Up-regulation of FasL expression was also reported in
melanomas (Hahne et al, 1996), glioblastomas (Saas et al, 1997),
hepatocellular carcinomas (Strand et al, 1996), lung carcinomas
(Niehans et al, 1997), liver metastases of colon adenocarcinomas
(Shiraki et al, 1997), colon carcinoma cell lines (O’Connell et al,
1996) and oesophageal carcinoma (Gratas et al, 1998). O’Connell
et al (1996) have proposed a hypothesis in which immune cells are
counterattacked by FasL-bearing tumours. Our analysis of primary
ovarian, endometrial and cervical carcinomas revealed a wide
range in the expression of FasL and only some of cervical and
endometrial carcinoma tissues demonstrated an up-regulation of
FasL expression. No up-regulation of FasL in endometrial and
ovarian carcinomas has also been reported recently (Takagi et al,
1998). Thus, the hypothesis in which immune cells are counter-
attacked by FasL-bearing tumour cells may not be generally
applicable in these gynaecological cancers.
Fas expression was demonstrated in the normal ovary,
endometrium and breast epithelial cells, where menstrual cycle-
dependent rounds of proliferation and regression due to apoptosis
were found (Leithauser et al, 1993; Guo et al, 1994; Tabibzadeh et
al, 1995). Levels of Fas expression were not very different among
these tissues. However, the level of FasL expression was much
higher in the endometrium compared with ovary and cervix (about
ninefold higher than in the ovary, and 12-fold higher than in the
cervix). FasL expression was also reported in normal uterine
tissues but not in ovarian tissues by RT-PCR and Western blot
analysis (Xerri et al, 1997). Detection of FasL in ovarian tissues in
our study may be only due to the greater sensitivity of our assay
system. The higher levels of FasL observed in normal endometrial
tissues compared with ovarian and cervical tissues appear to be
related to its greater menstrual cycle-dependent tissue proliferation
and regression.
In summary, we demonstrated a significant decrease in Fas
expression in gynaecological cancer tissues but not an increase in
FasL expression that was reported earlier in other carcinomas. We
found that only a limited number of our samples exhibited an
increase in FasL expression. However, since we analysed the gene
expression in the RNA extracted from blocks of tumour tissues
which may contain various percentages of tumour cells and normal
cells, it is possible that the obtained results may not really reflect
the expression of these genes in tumour cells. Especially, the pres-
ence of activated lymphocytes expressing large amounts of Fas
and FasL may affect the results. Combination of these results with
further studies using other techniques such as in situ hybridization
will be necessary to clarify this point.
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